CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT • US2183521028

39.82 USD
+0.19 (+0.48%)
At close: Feb 18, 2026
39.82 USD
0 (0%)
After Hours: 2/18/2026, 8:22:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year CORT was profitable.
  • In the past year CORT had a positive cash flow from operations.
  • Each year in the past 5 years CORT has been profitable.
  • CORT had a positive operating cash flow in each of the past 5 years.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

  • CORT's Return On Assets of 12.88% is amongst the best of the industry. CORT outperforms 93.19% of its industry peers.
  • CORT's Return On Equity of 16.79% is amongst the best of the industry. CORT outperforms 89.01% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.69%, CORT belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for CORT is significantly above the industry average of 12.64%.
  • The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(8.69%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 12.88%
ROE 16.79%
ROIC 8.69%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.32%, CORT belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
  • CORT's Profit Margin has declined in the last couple of years.
  • CORT has a Operating Margin of 8.85%. This is amongst the best in the industry. CORT outperforms 80.63% of its industry peers.
  • CORT's Operating Margin has declined in the last couple of years.
  • CORT's Gross Margin of 98.19% is amongst the best of the industry. CORT outperforms 96.86% of its industry peers.
  • CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.85%
PM (TTM) 14.32%
GM 98.19%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for CORT has been increased compared to 1 year ago.
  • The number of shares outstanding for CORT has been reduced compared to 5 years ago.
  • There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 15.80 indicates that CORT is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CORT (15.80) is better than 85.86% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.8
ROIC/WACC0.94
WACC9.23%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that CORT has no problem at all paying its short term obligations.
  • CORT has a Current ratio (3.14) which is in line with its industry peers.
  • A Quick Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
  • CORT's Quick ratio of 3.07 is in line compared to the rest of the industry. CORT outperforms 55.50% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.07
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • CORT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.16%.
  • Measured over the past years, CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.71% on average per year.
  • CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.92%.
  • CORT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.11% yearly.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%

3.2 Future

  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 46.02% on average per year.
  • CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.42% yearly.
EPS Next Y-23.36%
EPS Next 2Y-29.36%
EPS Next 3Y36.25%
EPS Next 5Y46.02%
Revenue Next Year17.6%
Revenue Next 2Y23.46%
Revenue Next 3Y25.84%
Revenue Next 5Y24.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 45.25, CORT can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, CORT is valued a bit cheaper than the industry average as 76.96% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, CORT is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 64.35, the valuation of CORT can be described as expensive.
  • CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 68.06% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. CORT is valued rather expensively when compared to this.
Industry RankSector Rank
PE 45.25
Fwd PE 64.35
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than 76.96% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaper than 83.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF 25.77
EV/EBITDA 51.93
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 36.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)4.66
EPS Next 2Y-29.36%
EPS Next 3Y36.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CORT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (2/18/2026, 8:22:50 PM)

After market: 39.82 0 (0%)

39.82

+0.19 (+0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)02-18
Inst Owners75.42%
Inst Owner Change-2.07%
Ins Owners6.65%
Ins Owner Change0.87%
Market Cap4.19B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts75
Price Target96.08 (141.29%)
Short Float %9.99%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.78%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)-25.93%
PT rev (3m)-30.34%
EPS NQ rev (1m)26.58%
EPS NQ rev (3m)-8.58%
EPS NY rev (1m)7.09%
EPS NY rev (3m)-6.6%
Revenue NQ rev (1m)3.75%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)-4.47%
Valuation
Industry RankSector Rank
PE 45.25
Fwd PE 64.35
P/S 5.65
P/FCF 25.77
P/OCF 25.72
P/B 6.63
P/tB 6.63
EV/EBITDA 51.93
EPS(TTM)0.88
EY2.21%
EPS(NY)0.62
Fwd EY1.55%
FCF(TTM)1.55
FCFY3.88%
OCF(TTM)1.55
OCFY3.89%
SpS7.05
BVpS6.01
TBVpS6.01
PEG (NY)N/A
PEG (5Y)4.66
Graham Number10.91
Profitability
Industry RankSector Rank
ROA 12.88%
ROE 16.79%
ROCE 10.07%
ROIC 8.69%
ROICexc 24.92%
ROICexgc 24.92%
OM 8.85%
PM (TTM) 14.32%
GM 98.19%
FCFM 21.93%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 36.2%
Cap/Sales 0.04%
Interest Coverage 250
Cash Conversion 245.43%
Profit Quality 153.21%
Current Ratio 3.14
Quick Ratio 3.07
Altman-Z 15.8
F-Score6
WACC9.23%
ROIC/WACC0.94
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-23.36%
EPS Next 2Y-29.36%
EPS Next 3Y36.25%
EPS Next 5Y46.02%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year17.6%
Revenue Next 2Y23.46%
Revenue Next 3Y25.84%
Revenue Next 5Y24.42%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-24.4%
EBIT Next 3Y37.86%
EBIT Next 5Y19.15%
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%

CORCEPT THERAPEUTICS INC / CORT FAQ

What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CORT.


Can you provide the valuation status for CORCEPT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.


Can you provide the profitability details for CORCEPT THERAPEUTICS INC?

CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.


What are the PE and PB ratios of CORCEPT THERAPEUTICS INC (CORT) stock?

The Price/Earnings (PE) ratio for CORCEPT THERAPEUTICS INC (CORT) is 45.25 and the Price/Book (PB) ratio is 6.63.